Hepatic Enzymes and Proteins as Prognostic Factors in Liver Disease Management

Abstract

Therefore, an article reviewing a hepatic enzyme/protein prognosis in liver disease studies is presented. Hepatocytic enzymes such as Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) being highly contributory indicators demonstrate mild to severe active liver inflammation and damage. Compared to this, it is worth noting that the so-called proteins which are referred to as albumin and alpha-fetoprotein (AFP) provide data on liver function and the severity of the disease, mainly in HCC (hepatocellular carcinoma). The review clarifies the role of these biomarkers in clinical practice attributing them to various indicators such as diagnosis, disease differentiation, treatment monitoring, and prognosis assessment. Difficulties, including variability, sensitivity problems, and complexity on the interpretation of results, are pointed out, showing the necessity of enhanced diagnosis tehnologies and personalized medicine strategies. The future of liver disease management concentrates on biomarker identification, better diagnostic equipment, embedding artificial intelligence, personized treatment, and involving authorities. The objective is to improve diagnostic accuracy, guid treatment outcomes, and apply ethics in genetic information. In summary, these pioneering technologies have the potential to make a substantial contribution to the level of liver disease treatment, provided that we address the connected problems, which will consequently result in better patients’ outcomes and quality of care.